ICYMI: Kanuma for Lysosomal Acid Lipase Deficiency Now Approved in England
source: shutterstock.com

ICYMI: Kanuma for Lysosomal Acid Lipase Deficiency Now Approved in England

In 2015, the United States approved Kanuma (sebelipase alfa) for the treatment of infants living with rare lysosomal acid lipase deficiency. However, the therapy was not approved in other countries;…

Continue Reading ICYMI: Kanuma for Lysosomal Acid Lipase Deficiency Now Approved in England
Guideline-Based Care Might Reduce Cerebrovascular Illness in Sickle Cell Disease
source: shutterstock.com

Guideline-Based Care Might Reduce Cerebrovascular Illness in Sickle Cell Disease

According to a story from Healio, a recent study has found that use of hydroxyurea in alignment with treatment guidelines has the potential to bring down symptoms of cerebrovascular disease…

Continue Reading Guideline-Based Care Might Reduce Cerebrovascular Illness in Sickle Cell Disease
Does Brain Inflammation Play a Role in Alzheimer’s Disease?
source: shutterstock.com

Does Brain Inflammation Play a Role in Alzheimer’s Disease?

Neurogeneticist Michael Nalls of the US National Institute on Aging recently told Science Alert that a 2022 study, published in the Journal of Alzheimer’s Disease, completely changed their discovery approach.…

Continue Reading Does Brain Inflammation Play a Role in Alzheimer’s Disease?
Researchers Identify Potential CDKL5 Treatment Target
https://pixabay.com/en/epilepsy-seizure-stroke-headache-623346/

Researchers Identify Potential CDKL5 Treatment Target

  As it stands today, there are no cures for CDKL5 deficiency disorder. Treatment is symptomatic and supportive, and includes physical, occupational, and speech therapy. CDKL5 deficiency disorder causes seizures,…

Continue Reading Researchers Identify Potential CDKL5 Treatment Target
A Phase 1/2 Trial on AIV001 for Basal Cell Carcinoma is Now Complete
source: shutterstock.com

A Phase 1/2 Trial on AIV001 for Basal Cell Carcinoma is Now Complete

  AIV001 (axitinib): a potential, non-surgical therapeutic option for people with basal cell carcinoma (BCC). AiViva Biopharma describes AIV001 as: a novel formulation of a multi-kinase inhibitor combined with AiViva’s…

Continue Reading A Phase 1/2 Trial on AIV001 for Basal Cell Carcinoma is Now Complete
Targeting the Bile Acid-Triggered Pathways Could be Key for Pediatric NASH
source: shutterstock.com

Targeting the Bile Acid-Triggered Pathways Could be Key for Pediatric NASH

According to a story from Healio, Rohit Kohli, MBBS, MS, division chief of gastroenterology, hepatology and nutrition at Children’s Hospital Los Angeles, spoke at the World Congress on Insulin Resistance, Diabetes…

Continue Reading Targeting the Bile Acid-Triggered Pathways Could be Key for Pediatric NASH
Cancer Survivor and Ataxia-Pancytopenia Syndrome Patient is Aiming to Make a Difference
source: shutterstock.com

Cancer Survivor and Ataxia-Pancytopenia Syndrome Patient is Aiming to Make a Difference

Nathan Ehrlich, age 40, has had more health troubles than the average person, to say the least. As a teenager, he was diagnosed with leukemia. Thanks to the support of…

Continue Reading Cancer Survivor and Ataxia-Pancytopenia Syndrome Patient is Aiming to Make a Difference

Oral Arsenic Trioxide Regimen Effective for Treating APL, Study Results Suggests

  The 66th American Society for Hematology (ASH) Annual Meeting and Exhibition took place from December 7-10, 2023. During the meeting, researchers and other stakeholders shared insights into clinical trends,…

Continue Reading Oral Arsenic Trioxide Regimen Effective for Treating APL, Study Results Suggests
ICYMI: TAR-200 for High-Risk Non-Muscle-Invasive Bladder Cancer Granted Breakthrough Therapy Designation
source: shutterstock.com

ICYMI: TAR-200 for High-Risk Non-Muscle-Invasive Bladder Cancer Granted Breakthrough Therapy Designation

In the United States, Breakthrough Therapy designation is granted by the U.S. Food and Drug Administration (FDA) to expedite drug development and review. This designation is granted to therapies that…

Continue Reading ICYMI: TAR-200 for High-Risk Non-Muscle-Invasive Bladder Cancer Granted Breakthrough Therapy Designation
Carisma Therapeutics is Developing CT-0508 to Target HER2 Positive Cancers
source: shutterstock.com

Carisma Therapeutics is Developing CT-0508 to Target HER2 Positive Cancers

Carisma Therapeutics, the manufacturer of CT-0508, issued a press release stating that researchers are conducting a combination study using CAR-M cell therapy plus Keytruda (pembrolizumab) in the treatment of overexpressing…

Continue Reading Carisma Therapeutics is Developing CT-0508 to Target HER2 Positive Cancers
Vyjuvek for DEB Earns Orphan Drug Designation in Japan
source: pixabay.com

Vyjuvek for DEB Earns Orphan Drug Designation in Japan

Healio Psoriatic Disease recently reported that Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy designed for people with dystrophic epidermolysis bullosa (DEB), was granted Orphan Drug designation (ODD) by the Japanese…

Continue Reading Vyjuvek for DEB Earns Orphan Drug Designation in Japan
Alzheimer’s: A Neuroscientist at the OHSU Claims Scientists Missed a Major Form of Cell Death
source: pixabay.com

Alzheimer’s: A Neuroscientist at the OHSU Claims Scientists Missed a Major Form of Cell Death

Ferroptosis, a form of cell death, destroys microglia cells, which are associated with the brain’s immune system in vascular dementia and Alzheimer’s. Dr. Stephen Back suggested that attention had not…

Continue Reading Alzheimer’s: A Neuroscientist at the OHSU Claims Scientists Missed a Major Form of Cell Death
STUDY: Keytruda + mRNA-4157 (V940) Vaccine Reduced Risk of Severe Melanoma Recurrence
Source: https://pixabay.com/en/syringe-kanuelle-vaccination-1574486/

STUDY: Keytruda + mRNA-4157 (V940) Vaccine Reduced Risk of Severe Melanoma Recurrence

In an investor news release from December 2023, Moderna and Merck shared follow-up data from the Phase 2b KEYNOTE-492/mRNA-4157-P201 clinical trial. During the trial, researchers explored the impact of Keytruda…

Continue Reading STUDY: Keytruda + mRNA-4157 (V940) Vaccine Reduced Risk of Severe Melanoma Recurrence